A new gold-based drug slows tumor growth by 82% in animals and targets cancer cells more precisely than chemotherapy.

A new gold-based drug can slow tumor growth in animals by 82% and target cancers more selectively than standard chemotherapy ...

Agenus secures a $22M mortgage and announces a strategic realignment to focus on botensilimab/balstilimab in MSS colorectal ...

Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of ...

Kairos Pharma’s development pipeline targets drug resistance and immune suppression, two critical barriers to effective cancer treatment. The company's flagship program, ENV105, is designed to address ...

Kairos Pharma (KAPA) has selected IBN to spearhead its corporate communications efforts. Kairos Pharma’s development pipeline targets drug resistance and immune suppression, two critical barriers to ...

The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic ...

Patients with oncogenic-driven lung cancer account for approximately 40-50% of the lung cancer population. Oral pills are effective at controlling the disease, but patients are not cured due to the ...

Scientists at Weill Cornell Medicine have uncovered a critical mechanism driving the growth of treatment-resistant prostate ...

Xencor’s Plamotamab targets non-Hodgkin lymphoma and rheumatoid arthritis. Learn why XNCR stock could surge with these ...

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...